文献速递认知障碍与痴呆

唐氏综合征与常染色体显性阿尔茨海默病中tau蛋白扩散的比较:一项横断面研究

Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
PubMed 文献 · Lancet Neurol · 2024-01-01

本横断面观察研究比较了唐氏综合征与常染色体显性阿尔茨海默病患者的tau蛋白扩散幅度、空间范围和时间顺序。研究发现,尽管淀粉样蛋白后tau蛋白的一般进展顺序相似,但两组在tau负荷的空间分布、时间和幅度上存在细微差异。

要点

  • 唐氏综合征患者tau PET负荷最常出现在皮层下和内侧颞区。
  • 常染色体显性阿尔茨海默病患者tau PET负荷主要位于内侧颞叶。
  • 在给定淀粉样蛋白水平下,唐氏综合征患者全脑tau浓度高于常染色体显性阿尔茨海默病患者。

核心结论

  • 尽管唐氏综合征和常染色体显性阿尔茨海默病患者中淀粉样蛋白后tau蛋白的一般进展顺序相似,但两组在tau负荷的空间分布、时间和幅度上存在细微差异。
  • tau积累时间模式的差异可能影响临床试验中给药时机,而tau负荷的空间模式和幅度差异可能影响疾病进展。

研究设计与样本

  • 横断面观察研究,纳入来自两个队列研究的年龄≥25岁参与者。
  • 数据来自Dominantly Inherited Alzheimer's Network研究(DIAN-OBS和DIAN-TU;2008年至2022年在澳大利亚、欧洲和美国招募的常染色体显性阿尔茨海默病基因突变携带者及非携带者家族对照)和Alzheimer Biomarkers Consortium-Down Syndrome研究(2015年至2021年在英国和美国招募的唐氏综合征患者及同胞对照)。
  • 两个研究的对照合并为单一家族对照组;所有参与者完成结构MRI和tau PET(18F-flortaucipir)成像。
  • 应用高斯混合模型分别识别每个队列中tau PET高负荷区域和tau结合最早变化的区域,并估计区域tau PET负荷随皮层淀粉样蛋白负荷的变化函数。

主要发现

  • 纳入137名唐氏综合征患者(平均年龄38.5岁[SD 8.2],74名[54%]男性,63名[46%]女性)、49名常染色体显性阿尔茨海默病患者(平均年龄43.9岁[11.2],22名[45%]男性,27名[55%]女性)和85名家族对照(平均年龄41.5岁[12.1],28名[33%]男性,57名[67%]女性),均满足tau-PET成像的PET质量控制程序。
  • 134名(98%)唐氏综合征患者、44名(90%)常染色体显性阿尔茨海默病患者和77名(91%)对照在tau PET成像后3年内完成了淀粉样蛋白PET扫描。
  • 空间上,唐氏综合征患者tau PET负荷最常出现在皮层下和内侧颞区,而常染色体显性阿尔茨海默病患者主要位于内侧颞叶。
  • 全脑范围内,在给定淀粉样蛋白水平下,唐氏综合征患者tau浓度高于常染色体显性阿尔茨海默病患者。
  • 时间上,唐氏综合征患者中tau增加与淀粉样蛋白增加的关联强于常染色体显性阿尔茨海默病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In people with genetic forms of Alzheimer's disease, such as in Down syndrome and autosomal-dominant Alzheimer's disease, pathological changes specific to Alzheimer's disease (ie, accumulation of amyloid and tau) occur in the brain at a young age, when comorbidities related to ageing are not present. Studies including these cohorts could, therefore, improve our understanding of the early pathogenesis of Alzheimer's disease and be useful when designing preventive interventions targeted at disease pathology or when planning clinical trials. We compared the magnitude, spatial extent, and temporal ordering of tau spread in people with Down syndrome and autosomal-dominant Alzheimer's disease. METHODS: In this cross-sectional observational study, we included participants (aged ≥25 years) from two cohort studies. First, we collected data from the Dominantly Inherited Alzheimer's Network studies (DIAN-OBS and DIAN-TU), which include carriers of autosomal-dominant Alzheimer's disease genetic mutations and non-carrier familial controls recruited in Australia, Europe, and the USA between 2008 and 2022. Second, we collected data from the Alzheimer Biomarkers Consortium-Down Syndrome study, which includes people with Down syndrome and sibling controls recruited from the UK and USA between 2015 and 2021. Controls from the two studies were combined into a single group of familial controls. All participants had completed structural MRI and tau PET (18F-flortaucipir) imaging. We applied Gaussian mixture modelling to identify regions of high tau PET burden and regions with the earliest changes in tau binding for each cohort separately. We estimated regional tau PET burden as a function of cortical amyloid burden for both cohorts. Finally, we compared the temporal pattern of tau PET burden relative to that of amyloid. FINDINGS: We included 137 people with Down syndrome (mean age 38·5 years [SD 8·2], 74 [54%] male, and 63 [46%] female), 49 individuals with autosomal-dominant Alzheimer's disease (mean age 43·9 years [11·2], 22 [45%] male, and 27 [55%] female), and 85 familial controls, pooled from across both studies (mean age 41·5 years [12·1], 28 [33%] male, and 57 [67%] female), who satisfied the PET quality-control procedure for tau-PET imaging processing. 134 (98%) people with Down syndrome, 44 (90%) with autosomal-dominant Alzheimer's disease, and 77 (91%) controls also completed an amyloid PET scan within 3 years of tau PET imaging. Spatially, tau PET burden was observed most frequently in subcortical and medial temporal regions in people with Down syndrome, and within the medial temporal lobe in people with autosomal-dominant Alzheimer's disease. Across the brain, people with Down syndrome had greater concentrations of tau for a given level of amyloid compared with people with autosomal-dominant Alzheimer's disease. Temporally, increases in tau were more strongly associated with increases in amyloid for people with Down syndrome compared with autosomal-dominant Alzheimer's disease. INTERPRETATION: Although the general progression of amyloid followed by tau is similar for people Down syndrome and people with autosomal-dominant Alzheimer's disease, we found subtle differences in the spatial distribution, timing, and magnitude of the tau burden between these two cohorts. These differences might have important implications; differences in the temporal pattern of tau accumulation might influence the timing of drug administration in clinical trials, whereas differences in the spatial pattern and magnitude of tau burden might affect disease progression. FUNDING: None.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Wisch JK, McKay NS, Boerwinkle AH, et al. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2024. PMID: 38631766. doi:10.1016/S1474-4422(24)00084-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。